FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4302761330> ?p ?o ?g. }

• W4302761330 endingPage "175883592211283" @default.
• W4302761330 startingPage "175883592211283" @default.
• W4302761330 abstract "To assess the efficacy and safety of neoadjuvant docetaxel + cisplatin chemotherapy with androgen deprivation therapy for the treatment of locally advanced prostate cancer (PCa) in patients harboring germline DNA damage repair genes (gDDR) defects.We conducted a prospective observational study in patients with locally advanced PCa confirmed with gDDR defects through next-generation sequencing. All patients received either docetaxel + cisplatin (platinum-group) or docetaxel chemo-hormonal therapy (docetaxel group) followed by radical prostatectomy with extended lymphadenectomy. The primary end point was biochemical progression-free survival (bPFS) and secondary end points include postoperative pathological response and safety assessment during the study period.A total of 36 patients were included in the study, among whom 14 and 22 patients received docetaxel + cisplatin and docetaxel treatment, respectively. Down-staging of Tumor (T), Nodes (N), and Metastasis (M) stages was observed in 11 (78.57%) and 9 (40.9%) patients (p = 0.041), respectively, in the docetaxel + cisplatin group and docetaxel group. The median bPFS was 7.76 months (95% CI 0.770-14.748) and not reached in the docetaxel group and docetaxel + cisplatin group, respectively. bPFS was significantly longer in the docetaxel + cisplatin group (p = 0.039) with a hazard ratio of 0.386 (95% CI 0.151-0.987, p < 0.05). Furthermore, one patient discontinued docetaxel + cisplatin after second cycle due to severe liver insufficiency which was confirmed as viral hepatitis A and no significant perioperative complications was observed in either group.This study suggests that cisplatin may increase docetaxel anticancer activity with tolerable safety profile in patients with locally advanced PCa carrying gDDR defects in the neoadjuvant setting, a hypothesis which will require prospective, randomized confirmation." @default.
• W4302761330 created "2022-10-07" @default.
• W4302761330 creator A5008154260 @default.
• W4302761330 creator A5009027431 @default.
• W4302761330 creator A5013129340 @default.
• W4302761330 creator A5016243869 @default.
• W4302761330 creator A5026625013 @default.
• W4302761330 creator A5027842973 @default.
• W4302761330 creator A5057863237 @default.
• W4302761330 creator A5073325123 @default.
• W4302761330 creator A5077353181 @default.
• W4302761330 creator A5089344831 @default.
• W4302761330 date "2022-01-01" @default.
• W4302761330 modified "2023-10-18" @default.
• W4302761330 title "Efficacy of neoadjuvant docetaxel + cisplatin chemo-hormonal therapy versus docetaxel chemo-hormonal therapy in patients with locally advanced prostate cancer with germline DNA damage repair gene alterations" @default.
• W4302761330 cites W1699761476 @default.
• W4302761330 cites W2000197817 @default.
• W4302761330 cites W2027902748 @default.
• W4302761330 cites W2031663842 @default.
• W4302761330 cites W2086064725 @default.
• W4302761330 cites W2087481500 @default.
• W4302761330 cites W2116284235 @default.
• W4302761330 cites W2121167328 @default.
• W4302761330 cites W2126668914 @default.
• W4302761330 cites W2130803372 @default.
• W4302761330 cites W2143687146 @default.
• W4302761330 cites W2161112598 @default.
• W4302761330 cites W2213675269 @default.
• W4302761330 cites W2334063602 @default.
• W4302761330 cites W2462985846 @default.
• W4302761330 cites W2510940971 @default.
• W4302761330 cites W2592628645 @default.
• W4302761330 cites W2626902876 @default.
• W4302761330 cites W2788106879 @default.
• W4302761330 cites W2893760555 @default.
• W4302761330 cites W2897636829 @default.
• W4302761330 cites W2922433043 @default.
• W4302761330 cites W2951552980 @default.
• W4302761330 cites W2958370806 @default.
• W4302761330 cites W2971350849 @default.
• W4302761330 cites W2972985040 @default.
• W4302761330 cites W3016483659 @default.
• W4302761330 cites W3031939267 @default.
• W4302761330 cites W3134592109 @default.
• W4302761330 cites W3158710047 @default.
• W4302761330 cites W3207589459 @default.
• W4302761330 doi "https://doi.org/10.1177/17588359221128356" @default.
• W4302761330 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36199621" @default.
• W4302761330 hasPublicationYear "2022" @default.
• W4302761330 type Work @default.
• W4302761330 citedByCount "2" @default.
• W4302761330 countsByYear W43027613302023 @default.
• W4302761330 crossrefType "journal-article" @default.
• W4302761330 hasAuthorship W4302761330A5008154260 @default.
• W4302761330 hasAuthorship W4302761330A5009027431 @default.
• W4302761330 hasAuthorship W4302761330A5013129340 @default.
• W4302761330 hasAuthorship W4302761330A5016243869 @default.
• W4302761330 hasAuthorship W4302761330A5026625013 @default.
• W4302761330 hasAuthorship W4302761330A5027842973 @default.
• W4302761330 hasAuthorship W4302761330A5057863237 @default.
• W4302761330 hasAuthorship W4302761330A5073325123 @default.
• W4302761330 hasAuthorship W4302761330A5077353181 @default.
• W4302761330 hasAuthorship W4302761330A5089344831 @default.
• W4302761330 hasBestOaLocation W43027613301 @default.
• W4302761330 hasConcept C121608353 @default.
• W4302761330 hasConcept C126322002 @default.
• W4302761330 hasConcept C126894567 @default.
• W4302761330 hasConcept C143998085 @default.
• W4302761330 hasConcept C2776694085 @default.
• W4302761330 hasConcept C2778239845 @default.
• W4302761330 hasConcept C2780192828 @default.
• W4302761330 hasConcept C2781190966 @default.
• W4302761330 hasConcept C71924100 @default.
• W4302761330 hasConceptScore W4302761330C121608353 @default.
• W4302761330 hasConceptScore W4302761330C126322002 @default.
• W4302761330 hasConceptScore W4302761330C126894567 @default.
• W4302761330 hasConceptScore W4302761330C143998085 @default.
• W4302761330 hasConceptScore W4302761330C2776694085 @default.
• W4302761330 hasConceptScore W4302761330C2778239845 @default.
• W4302761330 hasConceptScore W4302761330C2780192828 @default.
• W4302761330 hasConceptScore W4302761330C2781190966 @default.
• W4302761330 hasConceptScore W4302761330C71924100 @default.
• W4302761330 hasLocation W43027613301 @default.
• W4302761330 hasLocation W43027613302 @default.
• W4302761330 hasLocation W43027613303 @default.
• W4302761330 hasOpenAccess W4302761330 @default.
• W4302761330 hasPrimaryLocation W43027613301 @default.
• W4302761330 hasRelatedWork W13394025 @default.
• W4302761330 hasRelatedWork W2036431359 @default.
• W4302761330 hasRelatedWork W2120479973 @default.
• W4302761330 hasRelatedWork W2176768908 @default.
• W4302761330 hasRelatedWork W2371287473 @default.
• W4302761330 hasRelatedWork W2374947457 @default.
• W4302761330 hasRelatedWork W2378605750 @default.
• W4302761330 hasRelatedWork W2735900144 @default.
• W4302761330 hasRelatedWork W2891028327 @default.
• W4302761330 hasRelatedWork W3030062260 @default.
• W4302761330 hasVolume "14" @default.

• next